Surface Oncology Stock Forecast, Price & News

-0.06 (-0.99 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume540,262 shs
Average Volume703,156 shs
Market Capitalization$261.01 million
P/E Ratio16.69
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter.

Surface Oncology logo

About Surface Oncology

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.52 out of 5 stars

Medical Sector

49th out of 842 stocks

Biological Products, Except Diagnostic Industry

8th out of 103 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

Is Surface Oncology a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Surface Oncology stock.
View analyst ratings for Surface Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Surface Oncology?

Wall Street analysts have given Surface Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Surface Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Surface Oncology's next earnings date?

Surface Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Surface Oncology

How were Surface Oncology's earnings last quarter?

Surface Oncology, Inc. (NASDAQ:SURF) posted its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.02. The firm had revenue of $1.63 million for the quarter.
View Surface Oncology's earnings history

How has Surface Oncology's stock been impacted by Coronavirus (COVID-19)?

Surface Oncology's stock was trading at $2.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SURF shares have increased by 153.6% and is now trading at $6.01.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SURF?

5 analysts have issued 12-month price targets for Surface Oncology's stock. Their forecasts range from $12.00 to $18.00. On average, they anticipate Surface Oncology's stock price to reach $15.20 in the next year. This suggests a possible upside of 152.9% from the stock's current price.
View analysts' price targets for Surface Oncology
or view top-rated stocks among Wall Street analysts.

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the following people:
  • Dr. Robert W. Ross, Pres, CEO & Director (Age 47, Pay $705.9k)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 58, Pay $672.51k)
  • Ms. Jessica Fees, Chief Financial Officer (Age 50)
  • Ms. Liisa I. Nogelo, Sec., Chief Compliance Officer & Chief Legal Officer (Age 50)
  • Ms. Lisa McGrath, Sr. VP of HR
  • Mr. Bob Steininger, Sr. VP of Chemistry, Manufacturing & Controls
  • Dr. Alison O'Neill M.D., Chief Medical Officer
  • Mr. Henry C. Rath, Chief Bus. Officer

What is Jeff Goater's approval rating as Surface Oncology's CEO?

5 employees have rated Surface Oncology CEO Jeff Goater on Jeff Goater has an approval rating of 100% among Surface Oncology's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Surface Oncology's key competitors?

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Momo (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA).

When did Surface Oncology IPO?

(SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.03%) and Cutler Group LP (0.00%). Company insiders that own Surface Oncology stock include David S Grayzel, Jeff Goater, Jessica Fees and Robert W Ross.
View institutional ownership trends for Surface Oncology

Which major investors are buying Surface Oncology stock?

SURF stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P..
View insider buying and selling activity for Surface Oncology
or or view top insider-buying stocks.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $6.01.

How much money does Surface Oncology make?

Surface Oncology has a market capitalization of $261.01 million and generates $126.16 million in revenue each year. The company earns $59.34 million in net income (profit) each year or $1.57 on an earnings per share basis.

How many employees does Surface Oncology have?

Surface Oncology employs 51 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is

Where are Surface Oncology's headquarters?

Surface Oncology is headquartered at 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.